These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 39023516)

  • 1. Cost analysis of patiromer vs sodium zirconium cyclosilicate for the treatment of hyperkalemia in Spain and the UK.
    Ramirez de Arellano A; Jakutis G; Hunt B
    J Med Econ; 2024; 27(1):1011-1017. PubMed ID: 39023516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Hospitalization for Heart Failure in Patients With Hyperkalemia Treated With Sodium Zirconium Cyclosilicate Versus Patiromer.
    Zhuo M; Kim SC; Patorno E; Paik JM
    J Card Fail; 2022 Sep; 28(9):1414-1423. PubMed ID: 35470055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of sodium zirconium cyclosilicate for hyperkalemia among patients with chronic kidney disease or heart failure in Kuwait.
    Elsisi GH; Mahmoud MMI; Al-Humood K; Al-Yousef A
    J Med Econ; 2024; 27(1):253-265. PubMed ID: 38318718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Patiromer Versus Sodium Zirconium Cyclosilicate for the Management of Acute Hyperkalemia.
    Rydell A; Thackrey C; Molki M; Mullins BP
    Ann Pharmacother; 2024 Aug; 58(8):790-795. PubMed ID: 37953506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic impact of the use of patiromer in chronic kidney disease or heart failure for the treatment of chronic hyperkalemia in Spain.
    de Sequera P; Bover R; Ivanova-Markova Y; Ivanova A; González-Domínguez A; Valls M; Campos V
    Nefrologia (Engl Ed); 2023; 43(6):721-730. PubMed ID: 38228463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
    Takkar C; Nassar T; Qunibi W
    Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Patiromer and Sodium Zirconium Cyclosilicate on Blood Pressure in Rats with Chronic Kidney Disease.
    Li L; Budden J; Quinn CM; Bushinsky D
    J Cardiovasc Pharmacol Ther; 2024; 29():10742484241227580. PubMed ID: 38311939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis.
    Shrestha DB; Budhathoki P; Sedhai YR; Baniya R; Cable CA; Kashiouris MG; Dixon DL; Kidd JM; Adhikari Y; Marasini A; Bhandari S
    Curr Ther Res Clin Exp; 2021; 95():100635. PubMed ID: 34367383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of sodium zirconium cyclosilicate for treating hyperkalemia among Chinese patients.
    Tian L; Fu S; Li M; Zhao X; Li H
    Front Public Health; 2023; 11():1196789. PubMed ID: 38145082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Strippoli GF
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013165. PubMed ID: 32588430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia.
    Bounthavong M; Butler J; Dolan CM; Dunn JD; Fisher KA; Oestreicher N; Pitt B; Hauptman PJ; Veenstra DL
    Pharmacoeconomics; 2018 Dec; 36(12):1463-1473. PubMed ID: 30194623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia.
    Meaney CJ; Beccari MV; Yang Y; Zhao J
    Pharmacotherapy; 2017 Apr; 37(4):401-411. PubMed ID: 28122118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Sodium Zirconium Cyclosilicate Plus Renin-Angiotensin-Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study.
    Dwyer JP; Agiro A; Desai P; Oluwatosin Y
    Adv Ther; 2023 Nov; 40(11):4777-4791. PubMed ID: 37606716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-effectiveness analysis of patiromer for the treatment of hyperkalemia in chronic kidney disease patients with and without heart failure in Spain.
    González-Juanatey JR; González-Franco Á; de Sequera P; Valls M; Ramirez de Arellano A; Pomares E; Nieves D
    J Med Econ; 2022; 25(1):640-649. PubMed ID: 35510569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical Costs in Patients with Hyperkalemia on Long-Term Sodium Zirconium Cyclosilicate Therapy: The RECOGNIZE II Study.
    Agiro A; Dwyer JP; Oluwatosin Y; Desai P
    Clinicoecon Outcomes Res; 2023; 15():691-702. PubMed ID: 37753303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis.
    Zhang Y; Xu R; Wang F; Liu Y; Xu J; Zhao N; Cheng F; Long L; Jia J; Lin S
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1057-1066. PubMed ID: 33459923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patiromer for the treatment of hyperkalemia.
    Colbert GB; Patel D; Lerma EV
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):563-570. PubMed ID: 32511052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Treating Patients with Chronic Kidney Disease and Prior Hyperkalemia with Renin-Angiotensin-Aldosterone System Inhibitor and Patiromer: A Swiss Public Healthcare Perspective.
    Fischer B; Serra A; Telser H
    Adv Ther; 2022 Jun; 39(6):2717-2730. PubMed ID: 35416597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
    Schaefer JA; Gales MA
    Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate.
    Oshima A; Imamura T; Narang N; Kinugawa K
    Clin Cardiol; 2021 Sep; 44(9):1272-1275. PubMed ID: 34263946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.